Media stories about OncoSec Medical (NASDAQ:ONCS) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. OncoSec Medical earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 44.8848353257749 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
ONCS has been the subject of several recent research reports. HC Wainwright set a $6.00 price target on OncoSec Medical and gave the company a “buy” rating in a research note on Friday, January 19th. Maxim Group set a $5.00 price target on OncoSec Medical and gave the company a “buy” rating in a research note on Monday, April 16th. Finally, Piper Jaffray initiated coverage on shares of OncoSec Medical in a research report on Friday, February 9th. They set an “overweight” rating and a $4.00 price objective for the company. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. OncoSec Medical has an average rating of “Buy” and an average target price of $4.50.
ONCS traded down $0.02 during trading on Tuesday, hitting $1.50. 350,904 shares of the stock traded hands, compared to its average volume of 1,170,873. OncoSec Medical has a twelve month low of $0.88 and a twelve month high of $2.95. The company has a market cap of $80.83, a P/E ratio of -1.42 and a beta of 3.05.
OncoSec Medical (NASDAQ:ONCS) last announced its quarterly earnings data on Friday, March 9th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.05). equities analysts expect that OncoSec Medical will post -0.73 earnings per share for the current year.
In other news, CEO Daniel J. O’connor acquired 16,667 shares of the stock in a transaction on Monday, February 5th. The stock was acquired at an average cost of $1.50 per share, for a total transaction of $25,000.50. Following the completion of the transaction, the chief executive officer now directly owns 16,667 shares in the company, valued at $25,000.50. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 5.50% of the stock is owned by insiders.
WARNING: “OncoSec Medical (ONCS) Earning Somewhat Favorable News Coverage, Analysis Shows” was posted by Macon Daily and is owned by of Macon Daily. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://macondaily.com/2018/04/24/oncosec-medical-oncs-earning-somewhat-favorable-news-coverage-analysis-shows.html.
About OncoSec Medical
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.